On Dec 06, major Wall Street analysts update their ratings for $Edwards Lifesciences (EW.US)$, with price targets ranging from $75 to $90.
Goldman Sachs analyst David Roman maintains with a buy rating, and adjusts the target price from $80 to $90.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $88.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $75 to $78.
TD Cowen analyst Josh Jennings maintains with a hold rating, and maintains the target price at $75.
Mizuho Securities analyst Anthony Petrone maintains with a buy rating, and sets the target price at $85.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
The outlook for Edwards Lifesciences appears increasingly positive following the company's analyst day and the introduction of new guidance. While the current valuation broadly mirrors expectations for Edwards' growth, continued adherence to this guidance could heighten investor interest, particularly leading up to moderate data revelations expected at TCT 2026.
Edwards Lifesciences presented its 2025 outlook and long-range plans during its Investor Day, addressing previous concerns about TAVR capacity issues and competitive pressures, which are anticipated to persist into 2025. Despite these challenges, the company's 2025 guidance excluding foreign exchange impacts was more optimistic than expected, projecting growth of 8%-10% compared to a consensus of 7.8%. This projection bolstered investor confidence, with analysts recognizing the company's solid positioning in attractive end-markets, multiple growth catalysts, and favorable valuation.
Following attendance at the annual Edwards Lifesciences analyst meeting, it was clear there is an emerging positive narrative for the company's future. The current market valuation of Edwards seems reasonable, pending further support from physician insights.
Edwards Lifesciences delivered a promising multiyear outlook during its annual investor day, reiterating its 2024 guidance and unveiling 2025 guidance that aligns with current market estimates.
Here are the latest investment ratings and price targets for $Edwards Lifesciences (EW.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
